Inari Medical, Inc. - NARI STOCK NEWS

Inari Medical (NASDAQ: NARI) reported a strong first quarter for 2022, achieving revenue of $86.8 million, a 51% increase year-over-year. The company treated 8,800 patients, a sequential rise of 14%, and launched the new Intri24 device, enhancing its product line. Despite a net loss of $3.1 million, Inari revised its full-year revenue guidance upward to between $360 million and $370 million. The improved outlook reflects robust growth in U.S. operations and new product introductions.

Inari Medical, Inc. (NASDAQ: NARI) announced its management will present at the Bank of America 2022 Healthcare Conference on May 12, 2022, at 10:40 a.m. PT in Las Vegas. The presentation focuses on the company's innovative solutions for treating venous diseases, including FDA-cleared thrombectomy devices designed to remove large clots effectively. A live audio webcast of the event will be available on the company's website for 90 days under the 'Investor Relations' section.

Inari Medical, Inc. (NASDAQ: NARI) will release its Q1 2022 financial results on May 4, 2022. The company aims to transform the treatment of venous diseases with innovative catheter-based thrombectomy devices. Inari's ClotTriever is FDA 510(k)-cleared for deep vein thrombosis treatment, while FlowTriever is cleared for pulmonary embolism. Following the earnings release, a conference call will be held to discuss financial results and updates. Interested parties can access the live call and webinar via the company's investor relations website.

Inari Medical, Inc. (NASDAQ: NARI) announced the completion of a public offering, selling an additional 300,000 shares after exercising an over-allotment option. The total number of shares sold reached 2,300,000, generating approximately $186.3 million in gross proceeds at a price of $81.00 per share. Major underwriters included BofA Securities and Morgan Stanley. The transaction was conducted under an effective shelf registration statement filed with the SEC.

Inari Medical, Inc. (NASDAQ: NARI) has announced a public offering of 2,000,000 shares at $81.00 per share, expected to close around March 15, 2022. The underwriters have a 30-day option to purchase an additional 300,000 shares. Proceeds from this offering will support Inari’s mission to treat patients with venous diseases using their innovative catheter-based systems. The offering is registered under an effective shelf registration statement filed with the SEC.

Inari Medical, Inc. (NASDAQ: NARI) has announced a public offering of 2,000,000 shares of its common stock, with a potential additional 300,000 shares available for underwriters. The offering is subject to market conditions and will be conducted under a previously filed effective shelf registration statement. Joint lead managers for the offering are BofA Securities and Morgan Stanley. The company's press release emphasizes the transformative impact of its medical devices aimed at treating venous diseases.

Inari Medical, Inc. (NASDAQ: NARI) announced the appointment of Robert Warner to its board of directors as a member of the Audit Committee. Warner brings extensive experience, having served in various executive roles at Alcon, including President of the U.S. and Canada. His leadership is anticipated to add significant value as Inari advances its mission to treat patients with venous diseases. The company specializes in minimally-invasive devices for treating deep vein thrombosis and pulmonary embolism, which are FDA-cleared and CE Mark approved.

Inari Medical reported strong financial results for Q4 2021, generating revenue of $83.2 million, a 71% increase year-over-year. For the full year, revenue reached $277 million, up 98% from 2020. The company treated 7,700 patients, a 15% rise from Q3, with over 90% from non-COVID cases. Gross margin for Q4 was 90.1%, while operating expenses rose to $73.2 million. Net income for Q4 was $1.1 million, down from $7 million in Q4 2020. Looking ahead, Inari provides 2022 revenue guidance of $350 million to $360 million.

On February 15, 2022, Inari Medical announced the enrollment of the first patient in the PEERLESS trial, a randomized controlled study comparing the FlowTriever system with catheter-directed thrombolysis for treating pulmonary embolism (PE). The trial aims to enroll 550 patients across 60 centers in the U.S. and Europe, with additional patients in a registry cohort for those contraindicated for thrombolytics. Experts express optimism that the trial will enhance understanding of PE treatment and generate valuable clinical data.